3

Use of Glycolysis Enhancing Drugs has Less Risk of Parkinson's Disease than 5α-reductase Inhibitors

**Background:** Terazosin and closely related α1-adrenergic receptor antagonists (doxazosin and alfuzosin; TZ/DZ/AZ) enhance glycolysis and reduce neurodeneration in animal models. Observational evidence in humans from several databases support this …